Systemic MMP inhibition for periodontal wound repair: results of a multi-centre randomized-controlled clinical trial


Abstract
Aim: This multi-centre, prospective, controlled trial was designed to examine the biological response of the matrix metalloproteinase (MMP) inhibitor subantimicrobial dose doxycycline (SDD) combined with access flap surgery on periodontal wound repair in patients with chronic severe periodontitis.

Material and Methods: Seventy subjects were enrolled into a 12-month, randomized, placebo-controlled, double-masked trial to evaluate disease response to 6 months therapy and ‘wash-out’ of either placebo or SDD (20 mg b.i.d.) + surgery. Primary outcome measure included clinical attachment levels (CAL) and secondary outcomes included probing depth (PD), bleeding on probing (BOP), as well as gingival crevicular fluid bone marker assessment [collagen telopeptides (ICTP)]. These measurements were taken at baseline through 12 months post-surgery and drug administration.

Results: Patients treated with SDD and surgery demonstrated stronger reductions in PD in surgically-treated sites of ≥7 mm as well as gains in CAL (p < 0.004). Furthermore, SDD + surgery resulted in short-term reductions in ICTP levels compared with placebo. Rebounds in ICTP levels and clinical parameters occurred when SDD was withdrawn.

Conclusions: The results from this multi-centre study suggests that SDD in combination with surgery improves the short-term response of periodontal therapy by reducing PD, increasing CAL gain and inhibiting early stage bone resorption.

Key words: doxycycline; matrix metalloproteinases; MMP; periodontal; wound healing

Accepted for publication 19 October 2008

Conflict of interest and source of funding statement
This study was supported by CollaGenex Pharmaceuticals, Inc., NIH/NCRR UL1R024986, and the Delta Dental Fund.

It is generally accepted that, although periodontal disease is initiated by the subgingival microflora, inflammatory mediators released by host cells within the gingival tissues are major factors responsible for the destruction of the supporting periodontal tissues (Kornman 2008). Microbial virulence factors trigger the release of host-derived enzymes such as proteases (e.g., matrix metalloproteinases or MMPs) that can lead to destruction of tooth-supporting tissues (Slots & Genco 1984, Socransky & Haftjke 1991, Gopalsami et al. 1993). MMPs are a family of endopeptidasas with activity against most extracellular macromolecules (Pussinen et al. 2007). Collagenases, a subclass of the MMP family, are a group of enzymes capable of disrupting the triple helix of type I collagen in physiological conditions, the primary structural component of the periodontium. A number of physiological events [i.e., embryonic development and tissue remodeling (Shi et al. 2007)] and pathologic conditions such as arthritis (Murphy & Nagase 2008) and cancer (Lopez-Otin & Matrisian 2007) are characterized by heightened MMP activity. Studies have shown elevated levels of collagenases and other host-derived proteases (e.g., cathepsins, elastase, trypases/trypsin like proteases) in inflamed gingiva, gingival crevicular fluid (GCF), and saliva of...
humans with periodontal disease (Golub et al. 1976, 1990, Sorsa et al. 1988). Therefore, the determination that periodontal tissue destruction is primarily due to the host response has created areas of research directed at altering an individual’s reaction to the bacterial challenge. Hence, new methods of host modulatory therapy for periodontal disease are being focused beyond the traditional control of tooth-associated microbial biofilms.

Tetracyclines (TCNs; including the semi-synthetic analogues, minocycline and doxycycline) are capable of inhibiting mammalian collagenase activity (Golub et al. 1997, 2001). TCN’s inhibitory effect on collagenases appears to occur through the drug’s ability to bind to zinc cations as well as calcium ions in the catalytic domain of the molecule (Golub et al. 1983, 1987). Furthermore, administration of low doses of subantimicrobial dose doxycycline (SDD; a tetracycline analogue) given 20 mg b.i.d. rather than the 50–100 mg capsules, typically administered as commercially available antibiotics, effectively inhibit collagenase activity in the gingival tissues as well as in GCF (Golub et al. 1998) without exerting direct effects on the subgingival microorganisms. Several clinical studies have demonstrated improvements in gingival healing when SDD is used in combination with traditional dental prophylaxis or SRP (Caton et al. 2000, 2001, Novak 2002, Preshaw et al. 2004). More recently, a modified-released SDD formulation containing 40 mg doxycycline once a day demonstrated similar positive results (Preshaw et al. 2008).

Many of the crucial cellular responses of early post-surgical wound healing, such as inflammatory infiltration, angiogenesis and re-epithelialization, are made possible through the action of MMPs (Tarlton et al. 1997). Expression of MMPs such as collagenases is elevated in acute wounds, and still greater levels are found in chronic wounds, indicating that uncontrolled proteolysis is a characteristic of retarded healing (Tarlton et al. 1997, Neely et al. 2000, Gu et al. 2002). Several members of the MMP family function as positive and, at times, negative regulators of repair processes (Gill & Parks 2008). MMPs have demonstrated functions in bone including degradation of collagen and other components of the bone matrix, migration and survival of bone cells, endochondral bone formation and bone resorption (Varghese 2006). Abnormal expression of MMPs may also lead to pathological conditions affecting bone and cartilage (Giannobile 2008). Our group previously demonstrated in a single centre, proof-of-concept investigation that the utilization of a 6-month dosing of SDD in combination with access flap surgery could reduce GCF levels of collagen telopeptides (ICTP) and reduce pocket depth in patients with severe periodontitis (Gapski et al. 2004, Goodson 2004). However, given the limited sample, a more expanded, multi-centre investigation was warranted to better characterize the responses to therapy. Therefore, the aim of this multi-centre study was to evaluate the effect of a MMP-inhibitor (MMPi) in the post-surgical would healing in a larger population with chronic periodontitis.

Materials and Methods
Study population
A written informed consent was provided for individuals willing to participate in this trial that met the inclusion and exclusion criteria outlined in a protocol approved by Institutional Review Board of Academic Health Centres at the University of Michigan, Boston University and the Stony Brook University. Three calibrated surgeons and three separate individual clinical examiners were utilized from each Clinical Centre. In order to minimize the impact of inter-examiner variability, all clinical measurements were conducted by the same examiner from each center for the duration of the study. Before study commenced, the study examiner was trained and practiced in each of the clinical measurements. Duplicate measurements were compared to ensure a standard deviation of <1.0 mm for repeated within-subject probing depth (PD) and clinical attachment level (CAL) measures. The human clinical trial was performed in accordance with CONSORT guidelines (Moher et al. 2001). Seventy subjects (aged 30–75 years) diagnosed with chronic severe periodontitis were enrolled into a double-masked, randomized, placebo-controlled, prospective, parallel arm multi-center trial during the period of 1999–2003. Patients were recruited from November of the year 1999 to July of 2002. These patients were followed until July of 2003 (Fig. 1). Pertinent inclusion criteria included patients with at least three teeth in the same sextant demonstrating both PD and CAL >5 to ≤12 mm and bleeding on probing (BOP) with at least 10 teeth in the functional dentition. Exclusion criteria included patients chronically treated (i.e., 2 weeks or more) with any medication known to affect periodontal status (i.e., antibiotics or NSAIDS); those who received antibiotics within 90 days of baseline (BL); patients possessing clinically significant or unstable organic diseases; patients displaying compromised healing potential such as those with con-
The study design is shown in Table 1.

Patients eligible to participate in the study received full mouth scaling and root planing within 90 days before BL. Fourteen days before surgery, subjects were re-examined (screening visit) and inclusion/exclusion criteria were reviewed. Subjects who still qualified for the study and required access flap surgery in a minimum of one sextant were randomized to receive either doxycycline hyclate 20 mg b.i.d. (Periostat®, Galderma Labs, Fort Worth, TX, USA) or placebo capsules b.i.d. for the treatment period of 6 months. Full mouth manual clinical measurements were recorded for all teeth within 2 weeks of the BL appointment. Six sites were measured around each tooth in the mouth (mesiobuccal, buccal, distobuccal, distolingual, lingual and mesiolingual) for PD, CAL, and BOP. At the same visit, GCF was collected before clinical measurements. Gingival tissue surrounding the site to be sampled was dried with gauze, and supragingival plaque was removed. A sterile cellulose strip (Periopaper®; IDE-Interstate, Amityville, NY, USA) was gently placed into the mesiobuccal aspect of each tooth sulcus or pocket until slight resistance was felt, and the GCF collected for 10 s. Following collection, the sample was kept on ice for transport to the laboratory and stored at −80°C. The frozen samples were then thawed at room temperature and proteins were eluted through five centrifugations at 1500 x g for 5 min with 20 μl phosphate-buffered saline (pH 7.4) containing 15 mM aprotinin, 1 mM PMSF and 0.1% of human serum albumin as previously described (Giannobile et al., 1995). GCF ICTP levels were quantified using radioimmunoassay (RIA; Dia-Sorin Inc., Stillwater, MN, USA).

<table>
<thead>
<tr>
<th>Event/time points</th>
<th>P-SC</th>
<th>SC</th>
<th>BL</th>
<th>M-1</th>
<th>M-2</th>
<th>M-3</th>
<th>M-6</th>
<th>M-9</th>
<th>M-12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical history</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full mouth measurements</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine pregnancy test</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-telopeptide level</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maintenance therapy</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dispense medication</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug accountability</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Bone marker (ICTP) analysis**

GCF was collected before clinical measurements. Gingival tissue surrounding the site to be sampled was dried with gauze, and supragingival plaque was removed. A sterile cellulose strip (Periopaper®; IDE-Interstate, Amityville, NY, USA) was gently placed into the mesiobuccal aspect of each tooth sulcus or pocket until slight resistance was felt, and the GCF collected for 10 s. Following collection, the sample was kept on ice for transport to the laboratory and stored at −80°C. The frozen samples were then thawed at room temperature and proteins were eluted through five centrifugations at 1500 x g for 5 min with 20 μl phosphate-buffered saline (pH 7.4) containing 15 mM aprotinin, 1 mM PMSF and 0.1% of human serum albumin as previously described (Giannobile et al., 1995). GCF ICTP levels were quantified using radioimmunoassay (RIA; Dia-Sorin Inc., Stillwater, MN, USA).

**Dispensing of study medication/assessment of compliance**

At the screening visit, qualifying patients were assigned a code and were then randomized by a computer software program to the drug or placebo group using block randomization method. At the BL visit, each patient was issued a 3-month supply of coded study medication including one container for AM and another for PM intake. Three months following surgery, subjects returned residual capsules and received an additional 3-month supply. The residual capsules were counted and retained at 3 and 6 months after BL. Patient compliance (as a percentage) with the dosing schedule was recorded.

**Adverse events**

All adverse events were recorded. The need to capture this information was not dependent upon whether the adverse event was associated with the use of the study medication or not. Adverse events resulting from concurrent illnesses or reactions to concurrent medications were also recorded. Each adverse event was evaluated for duration, intensity and relationship with the study medication or other causes. When the different intensities occurred more frequently than once a day, the maximum intensity for the event was recorded. If the intensity category changed over a number of days, then these mini-events or changes were recorded separately (i.e., having distinct onset days). The investigator used the criteria below as guidelines for determining the relationship of the adverse event to the study drug: (i) a temporal relationship existed between the event and the use of the drug; (ii) re-administration of study medication resulted in reappearance or worsening of the reaction; (iii) previous experience with the suspected drug resulted in a similar reaction; and (iv) the event was not related to any concomitant disease, pre-existing condition, other drug therapy or environmental

---

© 2009 John Wiley & Sons A/S
Journal compilation © 2009 John Wiley & Sons A/S
factors. One of the following determinations will then document the relationship of the adverse event to the study drug: not related, possible and probable.

**Statistical analyses**

Based upon data presented in Fig. 1 of Golub et al. 1997, we have 80% power for detecting a 30 pg/site difference in mean ICTP, assuming a standard error of about 50 pg/site and type I error rate of 5%, between 35 control patients and 35 SDD patients. For analysis, the primary outcome measure was considered CAL and secondary outcomes included PD, BOP, as well as GCF bone marker assessment ICTP. Patient group differences in demographics were compared with a Wilcoxon’s rank sum test for continuous measures and a $\chi^2$ test of association for categorical measures. For each time point, site-specific levels of CAL, PD and BOP were first averaged across each tooth of each subject. The subject-level means of CAL, PD, BOP and ICTP were estimated via generalized estimating equations (GEE) with an independence working correlation matrix; statistical significance was based upon GEE robust variance estimates to account for: (1) correlation of teeth from the same subject, and (2) temporal correlation of values from the same tooth. Results presented are based upon GEE models with effects for treatment, time and their interaction. Adjustment for differences among sites was also examined, but later excluded due to lack of statistical significance. Standard errors presented for each outcome at each time point are based upon the robust GEE variance estimates. Statistical significance was defined as any $p$-value $<$ 0.05; No adjustment was made for comparisons among multiple time points. Subjects with missing data were included in all analyses to the extent of the actual data that was collected on those subjects, i.e., an intent-to-treat analysis was used, and no missing data were inputted.

**Results**

**Demographics - BL data**

A total of 70 patients entered into the study; 35 were randomized to the SDD group and 35 to the placebo group. Thirty-two out of 35 patients in the drug group and 33 out of 35 in the placebo group completed the study for an overall drop-out rate of 7.1%. At BL, there were no statistically significant differences between groups regarding age and gender (Table 2). Twenty-six percent of SDD subjects reported current use of tobacco and 31% in the placebo group (Table 2, $p = 0.6$). In addition, no significant differences were noted between the treatment groups with respect to BL clinical para-

| Table 2. Baseline mean demographics, clinical ICTP characteristics of the subject population |
|---------------------------------|-----------------|-------------------------------|
| Age | Mean (SD) 51 (± 10) | 47 (± 9) | 0.21*
| % Males | 63 | 46 | 0.15
| Current smokers N (%) | 9 (26) | 11 (31) | 0.60
| BOP (%) | 95 | 90 | 0.95
| Mean (SD) 56 (± 22) | 61 (± 19) | 0.34
| Mean (SD) 3.7 (± 0.7) | 3.9 (± 0.5) | 0.19
| Mean (SD) 3.7 (± 0.9) | 3.7 (± 1.0) | 0.95
| Mean (SD) 80 (± 76) | 87 (± 70) | 0.70
| % of sites with PD > 5 mm N (%) | 15 (12) | 17 (10) | 0.22
*By Wilcoxon's rank sum test.
By $\chi^2$ test of association.

$N$, number; SD, standard deviation; BOP, bleeding on probing; PD, probing depth; CAL, clinical attachment level; ICTP, collagen telopeptide.

**Fig. 2.** Effect of subantimicrobial dose doxycycline (SDD) or placebo in combination with surgery on clinical parameters and collagen telopeptides (ICTP) for all sites receiving surgery. The shaded background depicts the time of SDD or placebo administration. The bars represent per-patient standard errors. $p$ values indicate significant treatment group differences at a time point as determined by generalized estimating equations (GEE). $N = 70$ subjects.
meters (PD, BOP and CAL), ICTP levels and percentage of sites with PD > 5 mm (Table 2).

Compliance
The mean overall drug compliance for the SDD-treated patients was 88.4% (range 0–114%) while the placebo-treated individuals displayed 89.2% compliance (range 3–100%). Patients had a tendency to be slightly more compliant in the morning than in the evening (90.8% versus 86.7%, respectively; \( p = 0.003 \)). One patient in the drug group showed low compliance (18%). Further, there were no statistical significant effects of compliance on any treatment differences.

Treatment outcomes - responses in clinical parameters and ICTP levels

Pooled surgical sites (All PD strata)
The mean per-patient means in BOP, PD, CAL and ICTP from BL for all surgical sites is shown in Fig. 2. As expected, both placebo and test groups demonstrated a statistically significant reduction in PD compared with BL, however, no differences between groups was found. Surgical therapy resulted in mean CAL gains in both groups \(( p < 0.05)\). In addition, SDD-treated subjects demonstrated statistically significant reduced GCF ICTP levels compared with placebo immediately after the surgery (2 months, \( p = 0.03 \)).

Moderate sites (BL PD 5–6 mm)
Mean per-patient averages in BOP, PD, CAL and ICTP levels from BL at surgical sites with a BL PD of 5–6 mm is shown in Fig. 3. Consistent with results from pooled PD strata, there were significant reductions in PD and gains in CAL compared with BL for both drug and control groups. In addition, SDD group demonstrated a statistically significant decreased expression of GCF ICTP levels compared with placebo immediately after the surgery (2 months, \( p = 0.03 \)). There was a statistically significant reduction in percentage of BOP sites at 3 months between drug and placebo groups \(( p = 0.02 \)). Both SDD and placebo groups showed comparable levels in percentage of sites BOP after the patients discontinued drug therapy \(( p > 0.05)\).

Deep sites (BL PD \( \geqslant 7 \) mm)
Figure 4 shows the mean per patient averages in BOP, PD, CAL and ICTP levels for initially deep probing sites. Greater reductions in PD were noted in this PD stratum for both SDD and placebo groups. The drug therapy resulted in greater reductions in PD compared with controls at 3 months \(( p = 0.004)\). In addition, SDD-treated patients demonstrated a statistically significant increase in CAL compared with placebo during the drug administration (3 months, \( p = 0.02 \); 6 months, \( p = 0.005 \)).

Adverse events
The distributions of the adverse events were correspondingly distributed between the test and placebo groups. Overall, 58 patients (28 drug and 28 placebo) reported total of 93 adverse events during the course of the study and that could be classified according to oral and systemic criteria (Table 3). Overall, adverse events affecting the oral soft and hard tissues included postsurgical pain and/or erythema (38.7% of events), tooth sensitivity (8.6% of events) and periodontal abscess (6.4% of events). Excluding pulpitis, tooth fracture and soft tissue lesions, the other events appeared to be due to the anticipated responses to surgery and was not attributable to the study medication. Two patients from the test group developed soft tissue oral lesions. One patient developed a soft tissue lesion at 3 months of the trial and it was diagnosed at 12 months as lichen planus. She received topical doses of fluocinonide to manage the area. The other patient developed oral ulcers 1 week after the surgery. The patient did not report other
episodes during the rest of the trial, although had a past history of such lesions. The systemic adverse events during the study included headaches (6.4% of events) and common cold (6.4% of events). Myocardial infarction occurred in a patient who had not received the medication. This event occurred soon before the BL appointment and therefore, the patient was exited from the study.

Discussion
This multi-center investigation sought to evaluate the potential additive effect of SDD to modulate wound repair in conjunction with periodontal surgery. The goal was to explore the clinical and biochemical impact of this drug on the modulation of wound healing post-surgically. Following mechanical therapy in the form of scaling and root planing, patients then received access flap surgery and were randomized to SDD or placebo groups for 6 months of drug therapy, followed by a 6-month "washout". The patients exhibited moderate to severe horizontal bone loss, not indicated for conventional regenerative therapy. Therefore, patients included in this trial exhibited bone loss patterns with limited treatment options. When SDD was administered in combination with surgery, greater wound repair was found in the form of PD reduction and increase in CAL compared with placebo (Figs 2–4). SDD therapy may promote more rapid wound maturation by inhibiting collagen disruption and promoting collagen neogenesis. Therefore, differences in timing, quality and quantity of wound consolidation in the periodontium might have promoted an additive therapeutic effect in the SDD patients. Further statistical analysis also revealed that there were limited centre effects (data not shown). In fact, the significant differences indicated in the plots remained significant (with nearly identical \( p \)-values) after adjusting for clinical site confounders.

In this study, the inhibition of MMP via SDD resulted in a decrease in the bone resorption biomarker, ICTP, levels at 2 months after the surgical therapy while placebo demonstrated increases in ICTP levels over the same observation period. ICTP reflects the amount of organic matrix being disrupted in alveolar bone (specifically collagen type I) following osteoclastic bone resorption. ICTP has been utilized as a bone resorption marker in several systemic disease states including osteoarthritis (Berger et al. 2005), rheumatoid arthritis (Chopin et al. 2008), osteochondrosis (Vervuert et al. 2007), primary tumours and metastasis (Kong et al. 2007) and many other skeletal conditions. It has been shown by histological human data that osteoclastic activity peaks immediately after the bone is exposed by surgical operations (Wilderman et al. 1970). Therefore, release of excessive osteoclastic collagenases (or MMP-13) may have increased the disruption of collagen type I in bone and consequently increased ICTP release in the placebo. SDD-treated subjects displayed lower levels of wound fluid ICTP after surgery compared with BL, suggesting a "bone-sparing effect" of the drug. In fact, some studies have demonstrated that chemically modified TCNs not only inhibit bone resorption through their ability to inhibit MMPs but also by inducing apoptosis of osteoclasts, by inhibiting osteoclastic resorption and by inhibiting osteoclastogenesis (Holmes et al. 2004). Hence, our findings have demonstrated that utilization of an MMPi may have a direct impact on post-surgical bone turnover. Although these findings are limited to this subset of patients from our trial, these results should encourage further exploration of the impact of host modulatory agents on bone maintenance.

The MMPs are a family of 23 endopeptidases in humans (Clark et al. 2008) that were originally described as cleaving extracellular matrix macromolecules, but it is now clear that they have much wider functionality (Clark et al. 2008). Control over MMP and/or tissue inhibitor of metalloproteinases activity in vivo occurs at different levels and involves factors such as regulation of gene expression, activation ofzymogens and inhibition of active enzymes by specific inhibitors. Nearly 60 different MMPs have been pursued as clinical candidates to date (Dorman et al. 2007).
Table 3. Percentages and distribution of adverse events during the course of the study

<table>
<thead>
<tr>
<th>Adverse event characteristics</th>
<th>Distribution of events N (%) Drug N (%) Placebo N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dental related</td>
<td></td>
</tr>
<tr>
<td>Post-surgical pain and/or erythema</td>
<td>36 (51.4)</td>
</tr>
<tr>
<td>Tooth sensitivity</td>
<td>8 (11.4)</td>
</tr>
<tr>
<td>Periodontal abscess</td>
<td>6 (8.5)</td>
</tr>
<tr>
<td>Tooth fracture</td>
<td>3 (4.2)</td>
</tr>
<tr>
<td>Pulpitis</td>
<td>2 (2.8)</td>
</tr>
<tr>
<td>Soft tissue lesion</td>
<td>2 (2.8)</td>
</tr>
<tr>
<td>Infection</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Gingival swelling</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Systemic Related</td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>6 (8.5)</td>
</tr>
<tr>
<td>Common Cold</td>
<td>6 (8.5)</td>
</tr>
<tr>
<td>Stomach pain</td>
<td>3 (4.2)</td>
</tr>
<tr>
<td>Depression/anxiety</td>
<td>3 (4.2)</td>
</tr>
<tr>
<td>Physical Injury</td>
<td>2 (2.8)</td>
</tr>
<tr>
<td>Ear pain</td>
<td>2 (2.8)</td>
</tr>
<tr>
<td>Lower back pain</td>
<td>2 (2.8)</td>
</tr>
<tr>
<td>Lethargy/drowsiness</td>
<td>2 (2.8)</td>
</tr>
<tr>
<td>Arthritis</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Ibuprofen exposure</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Sleep problems</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Facial rash</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Sinus allergy</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>High cholesterol</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Vascular surgery at both legs</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Shoulder pain</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>1 (1.4)</td>
</tr>
</tbody>
</table>

N, number of patient with adverse events.
*The patient was excluded before baseline visit, therefore no group was assigned.

Targeted indications included rheumatoid arthritis, cardiovascular diseases, periodontal disease and many others (Giannobile 2008). MMPs have been considered prognostic factors in various types of cancer as well as promising targets for cancer therapy (Mannello 2006). Although numerous drug therapies to inhibit MMPs have been explored, only one agent SDD is currently approved for clinical use (Corbitt et al. 2007). This multi-centre randomized-clinical trial has demonstrated positive effect of an MMPi, SDD on post-surgical wound healing in patients with severe chronic periodontitis, at soft and hard tissue level. These results should encourage future basic and translational research in order to find even more effective MMPis. The next generations of MMPi should have specificity, gained from an understanding not only of the catalytic domain structures but the role of extracatalytic motifs in substrate binding (Murphy & Nagase 2008). In fact, innovative approaches for the design of selective MMP inhibitors are currently being performed including the integration of medicinal chemistry structure-based properties and design features (Dorman et al. 2007). This approach, which includes privileged structures, molecular frameworks, bioisosteric and bioanalogous/isofunctional modifications may lead to more highly selective MMPis in the future.

Conclusions

Six-month administration of MMPi, SDD, displayed an enhanced periodontal post-surgical wound healing compared with placebo controls. Early, transient reductions in the bone resorption marker ICTP were also found in patients while on the drug, suggesting the potential of SDD to act as a bone-sparing agent.

Acknowledgements

The authors thank Dr. Christopher Powala for his assistance in the organization of the trial.

References


**Address:**
William V. Giannobile
Michigan Center for Oral Health Research
University of Michigan School of Dentistry
24 Frank Lloyd Wright Dr.
Lobby M Box 422
Ann Arbor MI 48106
USA
E-mail: wgiannob@umich.edu

---

**Clinical Relevance**

**Scientific rationale for the study:** The determination that periodontal tissue destruction is primarily due to the host response has created areas of research directed at altering an individual’s reaction to the bacterial challenge. Hence, new methods of host modulatory therapy for periodontal disease are being focused beyond the traditional control of tooth-associated microbial biofilms. **Principal findings:** This manuscript demonstrates that the utilization of a 6-month dosing of a MMP inhibitor, SDD in combination with access flap surgery enhances periodontal post-surgical wound healing compared with placebo. Furthermore, transient reductions in the bone resorption marker were also found in patients while on the drug, suggesting the potential of SDD to act as a bone-sparing agent. **Practical implications:** These results support and encourage further exploration of the impact of host modulatory agents for periodontal repair and bone maintenance.